Uncategorized
Phase I study for prevention of chemotherapy-induced peripheral neuropathy

AnHorn Medicines has dosed the first subject in the Phase I clinical trial of AH-008, a first-in-class neuroprotective candidate being developed to prevent chemotherapy-induced peripheral neuropathy (CIPN).
This milestone marks the clinical advancement of a novel therapeutic approach designed to address one of the most common and debilitating complications of cancer treatment.
CIPN is a frequent and dose-limiting side effect of widely used cancer therapies, including taxanes, platinum-based agents, vinca alkaloids, and antibody-drug conjugates (ADCs). CIPN can cause numbness, tingling, pain, and sensory impairment that often persist long after treatment ends.
Studies indicate that 60–70% of patients experience CIPN during or shortly after chemotherapy, and nearly one-third continue to suffer six months or longer post-treatment. Despite its substantial burden, no approved therapies currently exist to prevent CIPN, and treatment options for established neuropathy remain limited1.
Preventing CIPN
CIPN not only impacts patient quality of life but also forces oncologists to reduce chemotherapy doses, delay schedules, or discontinue therapy—compromising treatment outcomes.
By preventing nerve damage before it occurs, AH-008 has the potential to:
- Improve quality of life for patients undergoing chemotherapy
- Reduce treatment-related pain, numbness, and sensory dysfunction
- Preserve chemotherapy dose intensity and adherence
- Enable patients to remain on optimal anti-cancer regimens
- Reduce long-term healthcare costs associated with chronic neuropathy
“The economic burden of CIPN is estimated at approximately $17,000 per patient, translating into a total societal burden of up to $153 billion. Preventing CIPN represents one of the most significant unmet needs in supportive oncology today,” said Shu-Jen Chen, Chief Scientific Officer of AnHorn Medicines. “The successful first patient dosing in our Phase I study marks an important step toward developing a disease-modifying therapy that could protect patients from debilitating nerve damage while enabling them to receive the full benefit of cancer treatment.”
Market opportunity
Each year, millions of cancer patients worldwide receive neurotoxic chemotherapy agents associated with CIPN. As these regimens expand across global markets, CIPN remains one of the most common and clinically meaningful dose-limiting toxicities in oncology.
With no approved preventive therapies, the global addressable market for CIPN prevention is estimated at US$15-19 billion annually, underscoring the significant commercial opportunity for a first-in-class approach2.
The treatment-enabling paradigm of AH-008 is analogous to granulocyte colony-stimulating factors (G-CSF), such as Neulasta, which prevent chemotherapy-induced neutropenia and enable full-dose chemotherapy. Similarly, AH-008 may establish a new standard of care in supportive oncology by addressing a key toxicity that currently limits cancer treatment delivery.
References
- Seretny M, Currie GL, Sena ES, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain. 2014;155(12):2461-2470.
- Company calculation based on the size of chemotherapy new incidence patients per year in 16 major pharmaceutical markets.
The post Phase I study for prevention of chemotherapy-induced peripheral neuropathy appeared first on Drug Discovery World (DDW).
Uncategorized
New webinar: Tackling drug discovery challenges in cancer research

Hosted by Drug Discovery World and supported by Sartorius and BioIVT, this webinar will explore the opportunities and challenges that exist within cancer research drug discovery and development.
You will hear from Dr Sudha Rao, Chief Scientific Officer of Kazia Therapeutics, Karol Budzik, PhD, Business Development Associate at Vyriad Therapeutics and Lars van der Veen, Chief Scientific Officer at iOnctura.
Presentations will cover how cancer treatments have shifted towards reprogramming the biology driving tumour growth, immune escape and treatment resistance, the trajectory that in vivo CAR-T treatments are taking, and how challenging tumours burdened by stroma and immune-mediated resistance can be tackled.
Q&A with the speakers follows the presentations.
The post New webinar: Tackling drug discovery challenges in cancer research appeared first on Drug Discovery World (DDW).
Uncategorized
Psilocybin proves promising in neuropathic pain mouse study
Amid the rise of psychedelics in the mental health space, researchers have begun to explore psilocybin as a treatment for chemotherapy-induced peripheral neuropathy.
Uncategorized
New Spectrometry Technique Could Aid Formulation Development
New Spectrometry Technique Could Aid Formulation Development
A new technique combining two forms of spectrometry could help biopharmaceutical companies improve their choice of formulation buffer for antibody manufacturing by revealing how molecular forms and three-dimensional shapes of complex biologics respond to their environment. That’s the view of Christian Bleiholder, PhD, a professor at Florida State University who helped develop the technique.
According to Bleiholder, what happens structurally when a complex biological molecule, such as an antibody or viral spike protein, binds to its target is currently poorly understood.
“This is where [this approach] can help with the bioprocessing and formulation,” he says, as structural changes “can affect the lifespan [of the product] and lead to issues, such as aggregation.”
Because antibodies are complex, existing techniques tend to be powerful at different levels of complexity, he explains. Mass spectrometry is particularly powerful for distinguishing molecular composition, while structural approaches such as X-ray crystallography and cryo-electron microscopy can provide high-resolution structural information.
The challenge is understanding the link between these things within a heterogeneous sample, he says.
To overcome this, Bleiholder and his team worked with Bruker Daltonics to develop Tandem-Trapped Ion Mobility Spectrometry (Tandem-TIMS). This combines tandem ion mobility spectrometry with tandem mass spectrometry to disentangle three overlapping layers of molecular complexity: molecular form, three-dimensional shape, and binding or assembly state, he says.
He explains that, if the proteins have different structures, they can be characterized with tandem ion mobility spectrometry, and then mass spectrometry can be used to look at their molecular forms and binding states.
Going forward, Bleiholder hopes the technique can be used for formulation development but also earlier, during drug discovery of new products, such as multi-specific antibodies, to determine which molecular states are important and how those change when a biologic engages its target. He also plans to look at automating the technique.
Bleiholder spoke about using Tandem-TIMS at the Bioprocessing Summit in Boston earlier this year.
The post New Spectrometry Technique Could Aid Formulation Development appeared first on GEN – Genetic Engineering and Biotechnology News.
-
Uncategorized8 months agoNovartis buys Synnovation’s PI3Kα inhibitors for $3 billion
-
Endpoints News8 months ago
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
-
Uncategorized7 months agoOptical Pooled CRISPR Screen Reveals Regulators of NF-κB Dynamics in Human Cells
-
Uncategorized6 months ago
Relay’s PI3Kα inhibitor clears efficacy bar in Phase 2 vascular anomalies study
-
Uncategorized5 months ago
Hybrid solid−liquid optics enable scalable, high-resolution light-sheet microscopy across diverse immersion media
-
Fierce Biotech8 months ago
Scientists turn pig semen extract into eye drops that kill cancer in mice
-
Nature Biotechnology8 months ago
Sustained nitric oxide production by engineered E. coli remodels the tumor microenvironment and potentiates immunotherapy
-
Nature Biotechnology8 months ago
Mapping cis-regulatory mutations at scale in sorghum enables modulation of gene expression
Scan to Read